Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Immusoft Corporation is managing 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 3 distinct examiners and 3 distinct art units, indicating that the company's active prosecution is spread across multiple administrative channels. This level of dispersion means that each of the 3 pending office actions is being reviewed in a different section of the patent office, which may result in varied prosecution experiences and timelines for the applications in this portfolio.
The busiest examiner, WESTON, ALYSSA G, is responsible for 1 busiest examiner pending office action. Given the total of 3 pending office actions, the workload is evenly divided among the 3 distinct examiners, with each handling a single active matter for the portfolio. This lack of concentration among examiners suggests that no single individual has a dominant influence over the company's current patent outcomes. Because there are 3 distinct art units involved, practitioners must manage the portfolio across several different technical review groups. The presence of 1 busiest examiner pending office action against a total of 3 actions highlights that the prosecution effort is currently fragmented, requiring the company to address the specific requirements of 3 different examiners simultaneously.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| No statute on record | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WESTON, ALYSSA G | 1 | 59.8% | +50.9% |
| REGLAS, GEORGIANA C | 1 | 37.7% | +36.1% |
| REGA, KYLE THOMAS | 1 | 62.7% | +41.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16981618 | B CELLS GENETICALLY ENGINEERED TO SECRETE FOLLISTATIN AND METHODS OF USING THE SAME TO TREAT FOLLISTATIN-RELATED DISEASES, CONDITIONS, DISORDERS AND TO ENHANCE MUSCLE GROWTH AND STRENGTH | REGLAS, GEORGIANA C | 60d overdue |
| 17886337 | B CELLS FOR IN VIVO DELIVERY OF THERAPEUTIC AGENTS | WESTON, ALYSSA G | 46d overdue |
| 16607962 | B CELLS FOR IN VIVO DELIVERY OF THERAPEUTIC AGENTS AND DOSAGES THEREOF | REGA, KYLE THOMAS | — |
| Art Unit | Apps |
|---|---|
| 1633 | 1 |
| 1651 | 1 |
| 1636 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17886337 | B CELLS FOR IN VIVO DELIVERY OF THERAPEUTIC AGENTS | WESTON, ALYSSA G | 1633 | Other | Final Rejection | 46d overdue | Pending | Aug 11, 2022 |
| 16981618 | B CELLS GENETICALLY ENGINEERED TO SECRETE FOLLISTATIN AND METHODS OF USING THE SAME TO TREAT FOLLISTATIN-RELATED DISEASES, CONDITIONS, DISORDERS AND TO ENHANCE MUSCLE GROWTH AND STRENGTH | REGLAS, GEORGIANA C | 1651 | §103 | Final Rejection | 60d overdue | Pending | Sep 16, 2020 |
| 16607962 | B CELLS FOR IN VIVO DELIVERY OF THERAPEUTIC AGENTS AND DOSAGES THEREOF | REGA, KYLE THOMAS | 1636 | §112DP | Final Rejection | — | Pending | Oct 24, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial